Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka, 575018, India.
Sushrutha Ayurveda Hospital, Puttur, 574201, India.
Neurochem Int. 2024 Nov;180:105864. doi: 10.1016/j.neuint.2024.105864. Epub 2024 Sep 29.
Alzheimer's disease, a prevalent neurodegenerative disorder in the elderly, is characterized by the accumulation of senile plaques and neurofibrillary tangles, triggering oxidative stress, neuroinflammation, and neuronal apoptosis. Current therapies focus on symptomatic treatment rather than targeting the underlying disease-modifying molecular mechanisms and are often associated with significant side effects. Bacopa monnieri, a traditional Indian herb with nootropic properties, has shown promise in neurological disorder treatment from ancient times. However, its mechanisms of action in Alzheimer's disease remain elusive. In this study, a cellular model for Alzheimer's disease was created by treating differentiated IMR-32 cells with beta-amyloid, 1-42 peptide (Aβ). Additionally, a recovery model was established through co-treatment with Bacopa monnieri to explore its protective mechanism. Co-treatment with Bacopa monnieri extract recovered Aβ induced damage as evidenced by the decreased apoptosis and reduced reactive oxygen species production. Mass spectrometry-based quantitative proteomic analysis identified 21,674 peptides, corresponding to 3626 proteins from the Alzheimer's disease model. The proteins dysregulated by Aβ were implicated in cellular functions, such as negative regulation of cell proliferation and microtubule cytoskeleton organization. The enriched pathways include extracellular matrix organization and interleukin-4 and interleukin-13 signaling. Bacopa monnieri co-treatment showed remarkable restoration of Aβ altered proteins, including FOSL1, and TDO2. The protein-protein interaction network analysis of Bacopa monnieri restored proteins identified the hub gene involved in Alzheimer's disease. The findings from this study may open up new avenues for creating innovative therapeutic approaches for Alzheimer's disease.
阿尔茨海默病是一种常见的老年人神经退行性疾病,其特征是老年斑和神经纤维缠结的积累,引发氧化应激、神经炎症和神经元凋亡。目前的治疗方法侧重于症状治疗,而不是针对潜在的疾病修饰分子机制,并且常常伴有显著的副作用。Bacopa monnieri 是一种具有益智特性的传统印度草药,自古以来就显示出在治疗神经紊乱方面的潜力。然而,其在阿尔茨海默病中的作用机制仍不清楚。在这项研究中,通过用β-淀粉样蛋白 1-42 肽(Aβ)处理分化的 IMR-32 细胞,创建了阿尔茨海默病的细胞模型。此外,通过与 Bacopa monnieri 共同处理建立了恢复模型,以探索其保护机制。 Bacopa monnieri 提取物的共同处理恢复了 Aβ 诱导的损伤,表现为凋亡减少和活性氧产生减少。基于质谱的定量蛋白质组学分析鉴定出 21674 个肽段,对应于阿尔茨海默病模型中的 3626 种蛋白质。Aβ 调节失调的蛋白质参与细胞功能,如细胞增殖的负调节和微管细胞骨架组织。富集的途径包括细胞外基质组织和白细胞介素 4 和白细胞介素 13 信号传导。 Bacopa monnieri 的共同处理显示出 Aβ 改变的蛋白质的显著恢复,包括 FOSL1 和 TDO2。 Bacopa monnieri 恢复蛋白的蛋白质-蛋白质相互作用网络分析确定了涉及阿尔茨海默病的关键基因。这项研究的结果可能为阿尔茨海默病的创新治疗方法开辟新的途径。